BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vesanoid (Tretinoin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vesanoid (Tretinoin)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07079696-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT07079696)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Investigating the Thera
 peutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Pat
 ients With 15q11-13 Duplication Syndrome\nEstimated primary completion: Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tretinoin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 79696
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348107-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Vesanoid (Tretinoin): Phase 1 readout est. (NCT07348107)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1.\nStudy: ATRA and SDK002 in Comb
 ination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advance
 d Pancreatic Ductal Adenocarcinoma.\nEstimated primary completion: March 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tretinoin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07348107
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932288-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Vesanoid (Tretinoin): Phase 4 readout est. (NCT07932288)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 4.\nStudy: Clinical Evaluation of 
 an Oil-Balancing Facial Sunscreen With Topical Tretinoin\nEstimated primar
 y completion: May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tretinoin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07932288
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646666-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT06646666)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: ARTA-based Chemo-free B
 ridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ine
 ligible for HDCT and ASCT\nEstimated primary completion: 1 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tretinoin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06646666
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05345002-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT05345002)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: All-Trans Retinoic Acid
  (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma\nEstimated pri
 mary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tretinoin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05345002
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06358677-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT06358677)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Topical Tretinoin Proph
 ylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors\n
 Estimated primary completion: July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06358677
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187505-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Vesanoid (Tretinoin): Phase na readout est. (NCT07187505)
DESCRIPTION:Vesanoid (Tretinoin)\, phase na\, Acute Myeloid Leukemia.\nStud
 y: Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelo
 cytic Leukemia\nEstimated primary completion: 1 July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07187505
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586826-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT07586826)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Romiplostim N01 Plus AT
 RA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Com
 plete Remission of Gynecologic\, Breast\, or Lung Solid Tumors\nEstimated 
 primary completion: 31 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07586826
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586813-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT07586813)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Romiplostim N01 Plus AT
 RA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Com
 plete Remission of Gastrointestinal Solid Tumors\nEstimated primary comple
 tion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tretinoin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07586813
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01409161-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT01409161)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in 
 Treating Patients With Previously Untreated Acute Promyelocytic Leukemia\n
 Estimated primary completion: 18 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT01409161
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597395-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Vesanoid (Tretinoin): Phase 3 readout est. (NCT07597395)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 3.\nStudy: ATRA for Management of 
 Primary ITP\nEstimated primary completion: 30 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07597395
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528769-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT06528769)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Study of All-Trans Reti
 noic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06528769
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07626398-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Vesanoid (Tretinoin): Phase 2/3 readout est. (NCT07626398)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2/3.\nStudy: All-Trans Retinoic Ac
 id for the Treatment of Hemophagocytic Lymphohistiocytosis\nEstimated prim
 ary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tretinoin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07626398
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241276-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280629
DTEND;VALUE=DATE:20280630
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT04241276)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: A Randomised Trial of A
 TRA in a Novel Drug Combination for Pancreatic Cancer\nEstimated primary c
 ompletion: 29 June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tretinoin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04241276
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07842887-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Vesanoid (Tretinoin): Phase 1 readout est. (NCT07842887)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1.\nStudy: Phase 1 Study of ATRA P
 lus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI 
 Resistance\nEstimated primary completion: 1 October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07842887
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07278908-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Vesanoid (Tretinoin): Phase 2/3 readout est. (NCT07278908)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2/3.\nStudy: Avatrombopag Combined
  With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocy
 topenia\nEstimated primary completion: December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07278908
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841952-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Vesanoid (Tretinoin): Phase na readout est. (NCT06841952)
DESCRIPTION:Vesanoid (Tretinoin)\, phase na\, Acute Myeloid Leukemia.\nStud
 y: Study of Tretinoin Capsules in Combination With Azacitidine and Venetoc
 lax in Treatment Naïve Participants With Acute Myeloid Leukemia\nEstimate
 d primary completion: 15 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tretinoin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06841952
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355855-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT07355855)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: A Clinical Study on the
  Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen 
 in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma\nEstimated 
 primary completion: January 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tretinoin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07355855
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706401-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Vesanoid (Tretinoin): Phase 3 readout est. (NCT06706401)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 3.\nStudy: Lymphocyte-Sparing And 
 Radio-Immunotherapy in Head and Neck Carcinoma\nEstimated primary completi
 on: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tre
 tinoin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06706401
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536413-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Vesanoid (Tretinoin): Phase 1/2 readout est. (NCT06536413)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1/2.\nStudy: ATRA and Carfilzomib 
 in Plasma Cell Myeloma Patients\nEstimated primary completion: July 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tretinoin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06536413
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636981-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT06636981)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: All Trans Retinoic Acid
  Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or
  Metastatic Triple Negative Breast Cancer：a Multi-center\, Multi-cohort 
 Phase II Trial\nEstimated primary completion: September 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tretinoin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06636981
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06703047-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20291120
DTEND;VALUE=DATE:20291121
SUMMARY:Vesanoid (Tretinoin): Phase 2 readout est. (NCT06703047)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 2.\nStudy: Tislelizumab Combined w
 ith Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metas
 tatic Esophageal Squamous Cell Carcinoma\nEstimated primary completion: 20
  November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/treti
 noin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06703047
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926607-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Vesanoid (Tretinoin): Phase 1/2 readout est. (NCT07926607)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Palbociclib\, All-Trans Retinoic Acid\, and Venetoclax in Relapsed or 
 Refractory Acute Myeloid Leukemia\nEstimated primary completion: 31 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tretinoin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079266
 07
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848568-3071@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20370630
DTEND;VALUE=DATE:20370701
SUMMARY:Vesanoid (Tretinoin): Phase 1/2 readout est. (NCT07848568)
DESCRIPTION:Vesanoid (Tretinoin)\, phase 1/2.\nStudy: Testing Safe Doses of
  Anti-Cancer Medicines\, 5-Flurouracil (5-FU) and Tretinoin (ATRA)\, Added
  to the Usual Cancer Treatment of Ependymoma\nEstimated primary completion
 : 30 June 2037. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/treti
 noin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07848568
URL:https://assetmemo.bio/drug/tretinoin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
